Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
WEST HOLLYWOOD, Calif., Dec. 20, 2022, ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only methylprednisolone (MP) well tolerated and shows efficacy for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 20, 2022 Category: Pharmaceuticals Source Type: clinical trials

Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
PRINCETON, N.J., Dec. 19, 2022. Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2022 Category: Pharmaceuticals Source Type: clinical trials

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC With Median Follow-Up of Approximately 12... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2022 Category: Pharmaceuticals Source Type: clinical trials

AbbVie Submits Supplemental New Drug Application to Support New Indication of Linzess for Functional Constipation in Children and Adolescents
NORTH CHICAGO, Ill., Dec. 16, 2022 . AbbVie today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 16, 2022 Category: Pharmaceuticals Source Type: clinical trials

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease
NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ( " Synaptogenix " or the " Company " ), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced topline... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 16, 2022 Category: Pharmaceuticals Source Type: clinical trials